Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

AL Amyloidosis

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

AL Amyloidosis

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 11 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
      source wording
      Source null

      Study evidence for this setting

      11 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT01222260 · Registry condition search · Scope: narrower

      Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis

      4 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT01570387 · Registry condition search · Scope: narrower

      A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis

      4 outcome links · 4 safety-group records · 0 quality-of-life measures

      →

      NCT02489500 · Registry condition search · Scope: narrower

      Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib

      4 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT02613182 · Registry condition search · Scope: narrower

      Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

      1 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT02632786 · Registry condition search · Scope: narrower

      The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis

      6 outcome links · 2 safety-group records · 2 quality-of-life measures

      →

      NCT02841033 · Registry condition search · Scope: narrower

      Daratumumab for the Treatment of Patients With AL Amyloidosis

      4 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT03154047 · Registry condition search · Scope: narrower

      Study in Subjects With Light Chain (AL) Amyloidosis

      1 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT04304144 · Registry condition search · Scope: narrower

      A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

      4 outcome links · 5 safety-group records · 0 quality-of-life measures

      →

      NCT04504825 · Registry condition search · Scope: narrower

      A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

      6 outcome links · 2 safety-group records · 2 quality-of-life measures

      →

      NCT04512235 · Registry condition search · Scope: narrower

      A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

      6 outcome links · 2 safety-group records · 2 quality-of-life measures

      →

      NCT05028374 · Registry condition search · Scope: narrower

      COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies

      2 outcome links · 3 safety-group records · 0 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
      1. release id
        clinical-indications-draft-1
        disease state id
        ds-al-amyloidosis
        binding id
        ncit-C158963
        source collection
        ncit-concept
        source key
        C158963
        source excerpt
        Source null
        match status
        exact
        match note
        Source null
        recorded at
        2026-09-10T00:00:00Z
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice